The study found that a specific area of the hairfollicle helps start hair growth by reducing the blocking effects on certain cells and controlling growth signals.
Corticosterone inhibits GAS6, affecting hairfollicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfollicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
PP405 is not a cure for hair loss but may reactivate dormant hairfollicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.